Sirona Biochem Reports Positive Results in Safety Study for Anti-Aging Compound TFC-1326
16 Noviembre 2022 - 8:00AM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF)
(“
Sirona”) is pleased to announce positive results
of the clinical safety study for their novel anti-aging compound
TFC-1326 1% in formulation, now proven to be a non-irritant and
non-sensitizer. TFC-1326, Sirona’s lead anti-aging compound, will
soon enter a clinical trial designed to assess its potential to
reverse the effects of aging on facial skin, restoring lost volume
and reducing fine wrinkles.
The safety study, which was conducted in Europe
under the control of a dermatologist, is a Human Repeat Insult
Patch Test with Challenge (HRIPT). The main goal of the HRIPT is to
confirm that the application of the investigational product (under
maximizing conditions of exposure in a panel of healthy human adult
subjects) does not induce delayed contact sensitization and
secondarily, to assess the skin compatibility of the formulation.
TFC-1326 1% in formulation is a non-irritant and non-sensitizer, a
claim recognized in the industry based on these results and
accepted by global regulatory bodies.
The study population included 100 healthy
individuals aged 18-70. Applications were repeated 9-times to the
same site (induction site) over a period of 3 consecutive weeks.
After a minimal 2-week rest period, with no product application, a
single application of the investigational product was placed under
a patch to both the induction site and a new site, to reveal a
possible induced allergy (challenge phase). In parallel, distilled
water is placed under a patch at the same defined times as the
investigational product to act as a control site.
Sirona’s anti-aging compound at 1% in the
formulation did not cause irritation, sensitization or allergy in
any subject.
The results of the HRIPT study are necessary to
move to the efficacy clinical trial which remains scheduled to
start in early December. A news release will be made announcing the
start of the trial and further details will be provided.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press
release, please contact:
Investor Enquiries:Jonathan WilliamsManaging
DirectorMomentum PRPhone: 1.450.332.6939Email:
jwilliams@momentumpr.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Sirona Biochem cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements. Forward-looking
statements are only predictions based upon current expectations and
involve known and unknown risks and uncertainties. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of release of the
relevant information, unless explicitly stated otherwise. Actual
results, performance or achievement could differ materially from
those expressed in, or implied by, Sirona Biochem’s forward-looking
statements due to the risks and uncertainties inherent in Sirona
Biochem’s business including, without limitation, statements about:
the progress and timing of its clinical trials; difficulties or
delays in development, testing, obtaining regulatory approval,
producing and marketing its products; unexpected adverse side
effects or inadequate therapeutic efficacy of its products that
could delay or prevent product development or commercialization;
the scope and validity of patent protection for its products;
competition from other pharmaceutical or biotechnology companies;
and its ability to obtain additional financing to support its
operations. Sirona Biochem does not assume any obligation to update
any forward-looking statements except as required by law.
BMO Short Term Bond Inde... (TSX:ZSB)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
BMO Short Term Bond Inde... (TSX:ZSB)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024